
Contents

Part I Immune-Mediated Myopathies

1	Introduction to Immune-Mediated Myopathies	3
1.1	Normal Skeletal Muscle	3
1.2	Immunometabolism of Skeletal Muscle	3
1.3	Immune Cells and Inflammatory Myopathies	5
1.4	Interferons in Inflammatory Myopathies	6
1.5	Conclusion	6
	References	7
2	Diagnostic Evaluation of Immune-Mediated Myopathies	9
2.1	Introduction	9
2.2	Clinical Features	9
2.3	Serum Muscle Enzymes	10
2.4	Electrodiagnostic Studies	10
2.4.1	Nerve Conduction Studies	11
2.4.2	Electromyography	11
2.5	Muscle Imaging	15
2.5.1	Muscle MRI and Muscle Biopsy for IIM Diagnosis	15
2.6	Autoantibodies in Myositis	16
2.7	Muscle Biopsy	17
2.8	Conclusion	19
	References	19
3	Classification of Immune-Mediated Myopathies	21
3.1	Introduction	21
3.2	Dermatomyositis	21
3.3	Sporadic Inclusion Body Myositis	27
3.4	Immune-Mediated Necrotizing Myopathy	28
3.5	Antisynthetase Syndrome	29
3.6	Overlap Myositis	30
3.7	Antimitochondrial M2-Associated Myopathy	31
3.8	Anti-Program Cell Death 1/PD-1 Ligand Inhibitor-Associated Myositis	31

3.9	Polymyositis.....	32
3.10	Conclusion.....	32
	References.....	32
4	Idiopathic Inflammatory Myopathies.....	37
4.1	Introduction.....	37
4.2	Dermatomyositis.....	37
4.2.1	Introduction.....	37
4.2.2	Pathological Criteria for DM.....	42
4.2.3	Pathophysiology of DM.....	45
4.2.4	Juvenile Manifestations of DM and Inherited Interferonopathies.....	50
4.2.5	Treatment in DM.....	52
4.2.6	Cancer and DM.....	52
4.2.7	Conclusion.....	53
4.3	Sporadic Inclusion Body Myositis.....	54
4.3.1	Introduction.....	54
4.3.2	Nomenclature.....	55
4.3.3	Epidemiology.....	55
4.3.4	Clinical Features of sIBM.....	56
4.3.5	Anti-cN1A Autoantibody.....	57
4.3.6	Microscopic Pathology.....	58
4.3.7	Diagnostic Criteria.....	58
4.3.8	Associated Disorders and Comorbidities.....	58
4.3.9	Progression.....	61
4.3.10	sIBM Therapeutics.....	61
4.3.11	Pathogenesis of sIBM.....	61
4.3.12	Conclusion.....	63
4.4	Polymyositis.....	64
4.5	Conclusion.....	65
	References.....	65
5	Specific Forms of Immune-Mediated Necrotizing Myopathies.....	73
5.1	Introduction.....	73
5.2	Diagnostic Criteria for IMNM.....	74
5.2.1	General Features of IMNM.....	74
5.2.2	Anti-SRP Autoantibodies.....	75
5.2.3	Anti-HMGCR Autoantibodies.....	75
5.3	Epidemiology.....	76
5.3.1	Prevalence, Incidence, and Risk Factors.....	76
5.3.2	Anti-SRP-Positive IMNM.....	76
5.3.3	Anti-HMGR-Positive IMNM.....	76
5.3.4	Seronegative IMNM.....	77
5.4	Clinical Features.....	77
5.4.1	Muscular Phenotype.....	77
5.4.2	Extramuscular Phenotype.....	78

5.5	Microscopic Pathology	79
5.5.1	General Pathology of IMNM.	79
5.5.2	Immunohistochemistry of IMNM	79
5.6	Disease Course and Prognosis	81
5.6.1	Seropositive IMNM.	81
5.6.2	Seronegative IMNM.	82
5.7	Pathogenesis of Seropositive IMNM.	82
5.7.1	Targets of Autoantibodies	83
5.7.2	Effects of Autoantibodies In Vitro	84
5.8	Treatment Recommendations for IMNM	84
5.9	Conclusions	86
5.10	Antisynthetase Syndrome	87
5.10.1	Introduction	87
5.10.2	Epidemiology.	87
5.10.3	Pathogenesis.	88
5.10.4	Diagnosis	90
5.10.5	Clinical Symptoms.	91
5.10.6	Myositis	91
5.10.7	Extramuscular Manifestations	92
5.10.8	Outcome and Prognosis	92
5.10.9	Overview of Treatment Possibilities	93
5.10.10	Conclusion.	94
5.11	IIMs that Mimic IMNM.	94
	References.	94
6	Overlap Myositis	101
	References.	102
7	Vasculitic Myopathy	103
7.1	Introduction	103
7.2	Large Vessel Vasculitis	105
7.3	Medium Vessel Vasculitis.	105
7.4	Small-Vessel Vasculitis	105
7.4.1	ANCA-Associated/Pauci-Immune Vasculitis	106
7.4.2	Immune-Complex Mediated Vasculitis	106
7.4.3	Anti-glomerular Basement Membrane Disease	107
7.4.4	Cryoglobulinemic Vasculitis	107
7.4.5	IgA Vasculitis (Henoch–Schönlein Purpura).	107
7.4.6	Hypocomplementemic Urticarial Vasculitis (Anti-C1q Vasculitis)	108
7.4.7	Variable Vessel Vasculitis.	108
7.4.8	Single-Organ Vasculitis	108
7.5	Skeletal Muscle Vasculitis	109
7.5.1	Takayasu Arteritis	110
7.5.2	Giant Cell Arteritis.	110

7.5.3	Polyarteritis Nodosa	111
7.5.4	Kawasaki Disease	112
7.5.5	Granulomatosis with Polyangiitis	114
7.5.6	Microscopic Polyangiitis	115
7.5.7	Eosinophilic Granulomatosis with Polyangiitis	116
7.5.8	Cryoglobulinemic Vasculitis	116
7.5.9	IgA Vasculitis	117
7.5.10	Anti-C1q Vasculitis	117
7.5.11	Cogan's Syndrome	117
7.5.12	Behçet's Disease	118
7.5.13	Single-Organ Vasculitis	118
7.5.14	Vasculitis Associated with Systemic Disease	119
7.6	Conclusion	119
	References	120
8	Sarcoid Myopathy and Other Immune-Mediated Granulomatous Myopathies	125
8.1	Introduction	125
8.2	Sarcoid Myopathy	125
8.2.1	Introduction	125
8.2.2	Clinical Features	126
8.2.3	Non-invasive Investigations	126
8.2.4	Muscle Biopsy	127
8.2.5	Management and Prognosis	128
8.3	Idiopathic Granulomatous Myositis	129
8.4	Giant Cell Myositis	129
8.5	Conclusion	130
	References	130
9	Paraproteinemia Associated Myopathy	131
9.1	Introduction	131
9.2	Amyloid Myopathy	131
9.3	Sporadic Late-Onset Nemaline Myopathy (SLONM)	133
9.4	Conclusion	134
	References	134
10	AntiAMA-M2 Myopathy	137
10.1	Introduction	137
10.2	Pathogenesis	137
10.3	Clinical and Laboratory Findings	138
10.4	Muscle Biopsy	139
10.5	Conclusion	139
	References	139
11	Paraneoplastic Myopathy	141
11.1	Introduction	141
11.2	Dermatomyositis (DM)	142

11.3	Sporadic Inclusion Body Myositis (sIBM)	144
11.4	Immune-Mediated Necrotizing Myopathy (IMNM)	144
11.5	Conclusions	145
	References	145
12	Mimics of Immune-Mediated Myopathy	149
12.1	Introduction	149
12.2	Muscular Dystrophies	149
12.2.1	Facioscapulohumeral Muscular Dystrophy	150
12.2.2	Dysferlinopathy	150
12.2.3	Calpainopathy	152
12.2.4	Role of MHC Staining	152
12.3	Metabolic Myopathies	153
12.3.1	Acid Maltase Deficiency (Pompe Disease)	153
12.3.2	McArdle's Disease	154
12.3.3	Mitochondrial Myopathies	155
12.4	Endocrine Myopathies	156
12.4.1	Thyroid Myopathies	156
12.4.2	Other Endocrine Myopathies	156
12.5	Nervous System Disease	157
12.6	Focal Disease	158
12.7	Conclusions	158
	References	159
13	Current Concepts and Future Prospects in Immune-Mediated Myopathies	161
13.1	Introduction	161
13.2	Interferons in Muscle Disease	162
13.2.1	IFN-I	162
13.2.2	IFN-II	163
13.2.3	IFN-III	163
13.2.4	Genetic Interferonopathies Share Common Features with DM	163
13.2.5	Skin Manifestations	164
13.2.6	Muscle Manifestations	164
13.2.7	IFN Pathway and DM-Specific Autoantibodies	165
13.2.8	IFN Pathway Is Activated in DM	165
13.2.9	IFN Production in DM	166
13.2.10	IFNs Induce Muscle Damage	167
13.2.11	Interferon Pathway Activation in ASS	167
13.2.12	Interferon Pathway Activation in sIBM	168
13.2.13	IFN and IMNM	170
13.2.14	Conclusion	170
13.3	Myositis Associated with Graft-Versus-Host Disease	171
13.3.1	Introduction	171
13.3.2	Pathophysiology of GVHD Myositis	172

13.3.3	Incidence and Onset of GVHD Myositis	173
13.3.4	Clinical Features	173
13.3.5	Muscle Enzymes and Autoantibodies	173
13.3.6	Imaging	174
13.3.7	Pathology	174
13.3.8	Association with GVHD	175
13.3.9	GVHD vs De Novo Myositis	175
13.3.10	Treatment	175
13.3.11	Outcome	176
13.3.12	Conclusion	177
13.4	SARS-CoV-2 Myopathy	177
13.4.1	Muscle Biopsy	179
13.4.2	Conclusion	179
13.5	Immune Checkpoint Inhibitors Associated Myopathy	179
13.5.1	Introduction	179
13.5.2	Epidemiology	180
13.5.3	Treatment Options for ICI-Induced Musculoskeletal Manifestations	181
13.5.4	Immunotherapy Type and Musculoskeletal Manifestations	181
13.5.5	Conclusion	181
	References	181

Part II Immune-Mediated Neuropathies

14 Introduction to Immune-Mediated Neuropathies:

	A Brief Overview of the Nervous System	193
14.1	Neurons	194
14.2	Synapse	195
14.3	Types of Neurons	195
14.3.1	Multipolar	195
14.3.2	Bipolar	196
14.3.3	Unipolar	196
14.4	Peripheral Nerve	196
14.5	Immune-Mediated Neuropathies	196
	References	197

15 Diagnostic Evaluation of Immune-Mediated Neuropathies 199

15.1	Introduction	199
15.2	Initial Steps	200
15.3	Clinical History	200
15.4	Neurological Examination	201
15.4.1	Type of Nerve Fiber Involvement	201
15.4.2	Distribution of Symptoms	202
15.5	Electrodiagnostic Studies	202
15.6	Laboratory Testing	203

15.6.1	Examination of the Cerebrospinal Fluid	204
15.6.2	Genetic Testing	204
15.6.3	Nerve Biopsy	205
15.6.4	Peripheral Nerve Imaging	205
15.6.5	Other Examinations	205
15.7	Conclusion	206
	References.	206
16	Classification of Immune-Mediated Neuropathies	207
16.1	Classification	208
17	Immune-Mediated Demyelinating Neuropathies.	209
17.1	Introduction	209
17.2	Guillain-Barré Syndrome.	209
17.2.1	Pathogenesis.	210
17.2.2	Clinical Features	212
17.2.3	Electrophysiological Findings	213
17.2.4	Laboratory Investigations.	213
17.2.5	Role of Nerve Biopsy in GBS	214
17.2.6	Treatment.	214
17.2.7	Paraneoplastic GBS	215
17.3	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)	215
17.3.1	Introduction	215
17.3.2	Clinical Features of Typical CIDP.	217
17.3.3	Electrodiagnostic Features and Ancillary Testing	217
17.4	Patterns Suggestive of Atypical CIDP or Disease Mimickers	218
17.4.1	Rapid Clinical Progression by Definition	218
17.4.2	Length-Dependent Sensory-Greater-Than-Motor, Axonal-Predominant Peripheral Neuropathy.	219
17.4.3	Non-Length-Dependent Sensory Ganglionopathy/Neuronopathy	219
17.4.4	Upper-Limb-Predominant Neuropathy	219
17.4.5	Sensory and Motor Demyelinating Neuropathy	220
17.4.6	Sensory and Motor Axonal Polyradiculoneuropathy	221
17.4.7	CIDP with a Paraprotein	221
17.4.8	Paraneoplastic CIDP	221
17.5	Conclusions	222
	References.	222
18	Immune-Mediated Axonal Neuropathies	227
18.1	Introduction	227
18.2	Vasculitic Neuropathy	228
18.2.1	Introduction	228
18.2.2	Classification	229
18.2.3	Clinical Features	230

18.2.4	Nonsystemic Vasculitic Neuropathy with Proximal Involvement (Nondiabetic Lumbosacral Radiculoplexus Neuropathy)	235
18.2.5	Subtypes	236
18.2.6	Imaging	239
18.2.7	Conclusion	239
18.3	Connective Tissue Disorders	240
18.4	Sarcoidosis	240
18.4.1	Neurosarcoidosis Consortium Consensus Group Definition and Consensus Diagnostic Criteria for Neurosarcoidosis	241
18.5	Immune-Mediated Gastrointestinal Disorders	242
18.5.1	Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis	243
18.5.2	Celiac Disease	243
18.6	Paraprotein-Associated Neuropathy	244
18.6.1	Epidemiology	245
18.6.2	Pathogenesis	245
18.6.3	IgM Paraproteinaemic Disorders	245
18.6.4	IgG or IgA Paraproteinaemic Disorders	248
18.6.5	IgM, IgG, or IgA Paraproteinaemic Disorders	249
18.6.6	Investigations	251
18.6.7	Nerve Biopsy	252
18.6.8	Conclusion	254
18.7	Paraneoplastic Disease	256
18.7.1	Types of Neuropathy	257
18.7.2	Diagnosis	258
18.7.3	Conclusion	259
18.8	Axonal GBS	259
18.9	Idiopathic Perineuritis	261
	References	261
19	Mimics of Immune-Mediated Neuropathy	269
19.1	Introduction	269
19.2	Diagnosis of Peripheral Neuropathies	269
19.3	Acquired Neuropathies	270
19.3.1	Metabolic Neuropathies	270
19.3.2	Toxic Neuropathies Metals	272
19.3.3	Drugs	273
19.3.4	Chemicals and Plants	274
19.3.5	Neurolymphomatosis	275
19.3.6	Hansen's Neuritis	276
19.3.7	Cholesterol Emboli Neuropathy	277
19.4	Conclusions	278
	References	278

20 Current Concepts and Future Prospects in Immune-Mediated Neuropathies 281

20.1 Immune Checkpoint Inhibitors 281

 20.1.1 Introduction 281

 20.1.2 Approach to Differential Diagnosis 282

 20.1.3 Conclusions 283

20.2 Coronavirus Disease 19 (COVID-19)/Coronavirus 2 (SARS-CoV-2) Associated Peripheral Neuropathy 283

 20.2.1 Introduction 283

 20.2.2 Peripheral Nervous System Manifestations and Complications 284

20.3 Humoral Immune Endoneurial Microvasculopathy 284

 20.3.1 Introduction 284

 20.3.2 Conclusion 287

References 288